Sisene develops a new generation of antiangiogenic drugs with an original mode of action, at least as active as the previous ones, with lower expected side effects, especially because these products are derived from physiological proteins existing in the body of the patients (blood and tissues).
One of them , NOV C- ter, C terminal part of NOV ( Nephroblastoma Overexpressed ), a physiological protein, is an innovative patented product which has